【4502】武田薬

Protagonist Therapeutics社との真性多血症患者さんを対象としたrusfertideの第3相VERIFY試験の良好なトップライン結果について
2025-03-03(20:45)

関連タグ:








Better Health, Brighter Future

News Release

News Release

Protagonist Investor Conference Call and Webcast Details The dial-in numbers for Protagonist’s investor update on Monday, March 3rd at 8:30 am ET are: US-based Investors: 1-877-300-8521 International Investors: 1-412-317-6026 Conference Call ID: 1793905 https://viavid.webcasts.com/starthere.jsp?ei=1708360&tp_key=94f2832555

[1]

A responder is a patient who completed weeks 0–32 of the study, was not phlebotomy eligible and did not receive a section.

phlebotomy during weeks 20-32. To meet phlebotomy eligibility, patients in the 
				

関連タグ:



  Protagonist Therapeutics社との真性多血症患者さんを対象としたrusfertideの第3相VERIFY試験の良好なトップライン結果について







関連情報
曜日別開示状況
年月